Research Article

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

Figure 4

Forest plot of neurocognitive and neurologic adverse events compared between PCSK9 inhibitors and control treatment (placebo or ezetimibe). a Treatment with alirocumab Q2W; b Treatment with alirocumab Q4W.